Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval
Authors
Keywords
Denosumab, Bone metastasis, Skeletal-related events, Efficacy, Safety
Journal
Journal of Bone Oncology
Volume 33, Issue -, Pages 100416
Publisher
Elsevier BV
Online
2022-02-08
DOI
10.1016/j.jbo.2022.100416
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Role of RANKL in cancer development and metastasis
- (2021) Kazuo Okamoto JOURNAL OF BONE AND MINERAL METABOLISM
- Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group
- (2021) Evangelos Terpos et al. LANCET ONCOLOGY
- Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases
- (2021) Hiroaki Ikesue et al. SUPPORTIVE CARE IN CANCER
- Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art
- (2021) Veronica Mollica et al. Cancers
- Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study
- (2021) Evangelos Terpos et al. Blood Advances
- Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline
- (2020) Philip J. Saylor et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized, open-label, controlled trial of monthly oral minodronate or semiannual subcutaneous injection of denosumab for bone loss by androgen deprivation in Asian men with prostate cancer: the PRevention of Osteopenia with Minodronate And DEnosumab (PROMADE) study
- (2020) T. Yoshida et al. OSTEOPOROSIS INTERNATIONAL
- Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany
- (2020) Ingo Diel et al. SUPPORTIVE CARE IN CANCER
- Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study
- (2020) Jin-Feng Huang et al. Annals of Translational Medicine
- BONE HEALTH IN CANCER: ESMO CLINICAL PRACTICE GUIDELINES
- (2020) R. Coleman et al. ANNALS OF ONCOLOGY
- A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial
- (2020) Solange Peters et al. Journal of Thoracic Oncology
- Targeting the RANKL/RANK/OPG Axis for Cancer Therapy
- (2020) Jie Ming et al. Frontiers in Oncology
- A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer
- (2020) Mark Clemons et al. EUROPEAN JOURNAL OF CANCER
- The Role of the RANKL/RANK Axis in the Prevention and Treatment of Breast Cancer with Immune Checkpoint Inhibitors and Anti-RANKL
- (2020) Aristofania Simatou et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Meta-analysis of clinical trials to assess denosumab over zoledronic acid in bone metastasis
- (2020) Jingcheng Chen et al. International Journal of Clinical Pharmacy
- Bone metastases
- (2020) Robert E. Coleman et al. Nature Reviews Disease Primers
- Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey
- (2020) Mashari AlZahrani et al. Journal of Bone Oncology
- Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Matthew Smith et al. LANCET ONCOLOGY
- Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Michael Gnant et al. LANCET ONCOLOGY
- Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases
- (2019) Yenny Angela et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review
- (2019) Momoko Takahashi et al. BMC CANCER
- Fracture incidence after denosumab discontinuation: Real-world data from a large healthcare provider
- (2019) Liana Tripto-Shkolnik et al. BONE
- Identifying skeletal-related events for prostate cancer patients in routinely collected hospital data
- (2019) Matthew G. Parry et al. Cancer Epidemiology
- Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial
- (2019) Robert Coleman et al. LANCET ONCOLOGY
- Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases
- (2018) Sven Otto et al. CANCER TREATMENT REVIEWS
- Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2018) Kenneth Anderson et al. JOURNAL OF CLINICAL ONCOLOGY
- Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study
- (2018) Noopur Raje et al. LANCET ONCOLOGY
- Treatment dynamics of bone-targeting agents among men with bone metastases from prostate cancer in the United States
- (2018) Anne M. Butler et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Economic burden of skeletal-related events in patients with multiple myeloma: analysis of US commercial claims database
- (2018) Debajyoti Bhowmik et al. JOURNAL OF MEDICAL ECONOMICS
- Examination of burden of skeletal-related events in patients naive to denosumab and intravenous bisphosphonate therapy in bone metastases from solid tumors population
- (2018) Debajyoti Bhowmik et al. CURRENT MEDICAL RESEARCH AND OPINION
- Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the United States
- (2018) David Henry et al. CURRENT MEDICAL RESEARCH AND OPINION
- Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases
- (2017) Andrew L. Himelstein et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Bone Formation Is Coupled to Resorption Via Suppression of Sclerostin Expression by Osteoclasts
- (2017) Masanori Koide et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology–Cancer Care Ontario Focused Guideline Update
- (2017) Catherine Van Poznak et al. JOURNAL OF CLINICAL ONCOLOGY
- Retrospective Review of Atypical Femoral Fracture in Metastatic Bone Disease Patients Receiving Denosumab Therapy
- (2017) Samantha Peiling Yang et al. ONCOLOGIST
- Longitudinal patterns of bone-targeted agent use among patients with solid tumors and bone metastases in the United States
- (2017) Yi Qian et al. SUPPORTIVE CARE IN CANCER
- Multiple Myeloma and Bone: The Fatal Interaction
- (2017) Silvia Marino et al. Cold Spring Harbor Perspectives in Medicine
- Renal impairment and use of nephrotoxic agents in patients with multiple myeloma in the clinical practice setting in the United States
- (2017) Yi Qian et al. Cancer Medicine
- Feasibility of extended dosing intervals of denosumab
- (2017) Jacob K Kettle et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- 1512PSAFETY OF DENOSUMAB (DMAB) IN PATIENTS (PTS) WITH STAGE 4 OR STAGE 5D CHRONIC KIDNEY DISEASE (CKD)
- (2017) G. Block et al. ANNALS OF ONCOLOGY
- Can we prevent BRCA1-associated breast cancer by RANKL inhibition?
- (2016) Joanne Kotsopoulos et al. BREAST CANCER RESEARCH AND TREATMENT
- Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents
- (2016) A. Lipton et al. CLINICAL CANCER RESEARCH
- Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics
- (2016) A. Lipton et al. EUROPEAN JOURNAL OF CANCER
- Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial
- (2016) Fred Saad et al. LANCET ONCOLOGY
- Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications
- (2015) Javier De Castro et al. Clinical Lung Cancer
- Hypocalcaemia in patients with metastatic bone disease treated with denosumab
- (2015) Jean-Jacques Body et al. EUROPEAN JOURNAL OF CANCER
- Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer
- (2015) Karim Fizazi et al. EUROPEAN UROLOGY
- Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS)
- (2015) Xiaoyan Zhang et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer
- (2015) Alison T. Stopeck et al. SUPPORTIVE CARE IN CANCER
- Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases
- (2015) Roger von Moos et al. SUPPORTIVE CARE IN CANCER
- Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche
- (2015) Michelle A. Lawson et al. Nature Communications
- Prevalence of renal impairment and use of nephrotoxic agents among patients with bone metastases from solid tumors in the United States
- (2015) Jorge Arellano et al. Cancer Medicine
- The pharmacokinetics and pharmacodynamics of denosumab in patients with advanced solid tumours and bone metastases: a systematic review
- (2014) Winnie Sohn et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update
- (2014) Salvatore L. Ruggiero et al. JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY
- Bone metastasis, skeletal-related events, and mortality in lung cancer patients: A Danish population-based cohort study
- (2014) Karynsa Cetin et al. LUNG CANCER
- Patients with bone metastases from solid tumors initiating treatment with a bone-targeted agent in 2011: a descriptive analysis using oncology clinic data in the US
- (2014) Rohini K. Hernandez et al. SUPPORTIVE CARE IN CANCER
- Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trials
- (2014) XIN WANG et al. Oncology Letters
- Short-term disability in solid tumor patients with bone metastases and skeletal-related events
- (2014) Yi Qian et al. JOURNAL OF MEDICAL ECONOMICS
- Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid
- (2013) Roger von Moos et al. SUPPORTIVE CARE IN CANCER
- Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors
- (2013) David Henry et al. SUPPORTIVE CARE IN CANCER
- Renal complications from bisphosphonate treatment
- (2013) Raimund Hirschberg Current Opinion in Supportive and Palliative Care
- Pain outcomes in patients with advanced breast cancer and bone metastases
- (2012) Charles S. Cleeland et al. CANCER
- Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid
- (2012) M. Martin et al. CLINICAL CANCER RESEARCH
- Population Pharmacokinetic Analysis of Denosumab in Patients with Bone Metastases from Solid Tumours
- (2012) Leonid Gibiansky et al. CLINICAL PHARMACOKINETICS
- Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
- (2012) Allan Lipton et al. EUROPEAN JOURNAL OF CANCER
- A single-dose study of denosumab in patients with various degrees of renal impairment
- (2012) Geoffrey A Block et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases
- (2011) F. Saad et al. ANNALS OF ONCOLOGY
- Incidence of bone metastases and skeletal-related events in breast cancer patients: A population-based cohort study in Denmark
- (2011) Annette Ø Jensen et al. BMC CANCER
- Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999–2006
- (2011) Nalini Sathiakumar et al. BREAST CANCER RESEARCH AND TREATMENT
- Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
- (2011) David H. Henry et al. JOURNAL OF CLINICAL ONCOLOGY
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
- (2011) Karim Fizazi et al. LANCET
- The Role of RANK-Ligand Inhibition in Cancer: The Story of Denosumab
- (2011) D. Castellano et al. ONCOLOGIST
- Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999–2006
- (2011) N Sathiakumar et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
- (2010) Alison T. Stopeck et al. JOURNAL OF CLINICAL ONCOLOGY
- Bisphosphonates: Mechanism of Action and Role in Clinical Practice
- (2009) Matthew T. Drake et al. MAYO CLINIC PROCEEDINGS
- Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate Therapy
- (2008) A. Lipton et al. CLINICAL CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started